Astex Pharmaceuticals, a pharmaceutical company developing small molecule therapeutics for oncology and diseases of the central nervous system, has earned a milestone payment from AstraZeneca for the first commercial sale of Truqap plus Faslodex for HR-positive, HER2-negative locally advanced or metastatic breast cancer in the U.S. following the U.S. FDA’s approval. Truqap is a first-in-class oral targeted inhibitor of the cancer-driving protein AKT, also known as PKB. AKT is an enzyme that p...